The GLP-1 Pipeline in 2026: Beyond Semaglutide and Tirzepatide
By GLPeptideSciences Editorial
The GLP-1 story didn’t end with semaglutide and tirzepatide — it accelerated. Here’s a neutral map of where the metabolic field is heading, with the one habit that matters most: check the trial stage before you get excited.
Approved and established
Semaglutide (GLP-1) and tirzepatide (dual GIP/GLP-1) are the anchors — both FDA-approved with large randomized trial programs behind them. They set the evidence bar everything else is measured against.
The next wave (investigational)
Several compounds are advancing through human trials but are not approved:
- Triple agonists (GLP-1 / GIP / glucagon) aiming for larger metabolic effects.
- Amylin-based combinations explored for additive weight effects.
- Oral formulations that try to deliver incretin effects without injection.
Each of these is at a different point on the evidence curve. “In a phase-3 trial” and “approved” are not the same claim, and “showed promise in a study” is weaker still.
How to read pipeline news
- Stage first. Preclinical < phase 1 < phase 2 < phase 3 < approved. Know which one a headline is describing.
- Endpoint honesty. Weight or A1c change in a controlled trial is meaningful; a surrogate marker in a small study is a hint, not a verdict.
- Comparator. “Better than placebo” is a lower bar than “better than an approved drug.”
The bottom line
The pipeline is genuinely exciting, but excitement and evidence aren’t the same currency. For the two compounds you can actually evaluate against approval-grade data today, start with our GLP-1 & Metabolic pillar.